EZH2 and breast carcinoma: As well-described epigenetic regulator of cell cycle progression [37] and cell lineage determination [68], EZH2 overexpression correlates with aggressiveness and poor survival in prostate, colorectal, and breast cancers, as well as melanomas [69,70,71,72].